TITLE

GENEREX EXPANDS PLAN FOR FDA IND FOR ORAL-LYN

PUB. DATE
May 2010
SOURCE
Biotech Business;May2010, Vol. 23 Issue 5, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports the move of Generex Biotechnology Corp. to include licensed and qualified nurse practitioners in plans for its U.S. Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for its oral insulin Generex Oral-lyn. Under the program, companies can provide early access to investigational drugs for patients having serious or life-threatening conditions for which no satisfactory alternative treatment is available. Oral-lyn will be given to patients having serious Type 1 or Type 2 diabetes mellitus.
ACCESSION #
49760957

 

Related Articles

  • Supplementary prescribing case study. Sewell, Gwendoline // Paediatric Nursing;Dec2006, Vol. 18 Issue 10, p14 

    A principle aim of supplementary prescribing is to enable faster access to medicines for people who have a chronic condition. The example of a young person with diabetes is used to demonstrate the benefits of nurse specialists being able to prescribe. The way in which prescribing requirements,...

  • Full prescribing rights in sight. Bishop, Tina // Practice Nurse;4/11/2008, Vol. 35 Issue 7, p7 

    The author comments on the removal of the last restrictions on the right of community nurses to prescribe in Great Britain. Legislation has been laid before parliament to enable qualified nurse prescribers to prescribe any controlled drug, subject to clinical and professional competence. The...

  • Independent and supplementary prescribing: an overview. Courtenay, Molly // Primary Health Care;Feb2006, Vol. 16 Issue 1, p21 

    The article discusses developments in nurse prescribing in Great Britain and explains the changes in the area. An estimated 28,000 district nurses (DN) and health visitors (HV) are qualified to prescribe from a list of appliances, dressings, pharmacy medicines and prescription-only medicines. A...

  • Nurse practitioners on the move in Victoria. Paul, Julie; Conte, Karen // Australian Nursing Journal;Oct2006, Vol. 14 Issue 4, p21 

    The authors reflect on the rewards and challenges they face as the first endorsed palliative care nurse practitioners in Victoria. Being endorsed as nurse practitioners enables us to prescribe from a limited drug formulary which includes most of the drugs that we generally use in palliative care...

  • Independent Nurse: Changes to prescribing laws hand nurses greater control. Moberly, Tom // GP: General Practitioner;1/29/2010, p4 

    The article reports on changes to prescribing rules for unlicensed medicines for nurses and pharmacist independent prescribers in Great Britain. The changes to the rules enable nurse independent prescribers to direct other healthcare workers, patients and carers to mix medicines in devices such...

  • Independent Nurse: Opinion - Online.  // GP: General Practitioner;1/29/2010, p14 

    The article presents readers' opinions on issues related to nursing. According to one reader, the decision of linking nurses' pay to productivity may have negative implications. Another reader comments that extended hours for nurses are nothing but a waste of time. Another reader writes that...

  • Independent nurse moniker dropped. Rillstone, Gerald // New Zealand Doctor;9/21/2005, p2 

    Reports on the decision of the New Zealand government to allow nurse practitioners to prescribe a range of medicines and controlled substances. Reaction of rural areas to the decision according to New Zealand Medical Association General Practitioner Council chair Peter Foley; Drugs and...

  • Human insulin analog.  // Geriatrics;Jul2000, Vol. 55 Issue 7, p24 

    Reports that the insulin glargine injection was approved by the United States Food and Drug Administration for the treatment of adult and pediatric patients with diabetes mellitus. Labeling and prescription of the drug; Main adverse events caused by the drug.

  • FDA Advisory Panel Gives Nod to Inhaled Insulin.  // Chain Drug Review;4/28/2014, Vol. 36 Issue 7, p229 

    The article informs that the U.S. Food and Drug Administration's advisory committee has recommended the approval of Afrezza, a form of insulin that is inhaled, by stating the benefits of inhaled insulin for diabetes patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics